Arcturus Therapeutics Holdings EBIT

Arcturus Therapeutics Holdings (ARCT) currently reports a EBIT of $-99M as of June 2026. That compares with $-58M in the prior-year period — down 71.1% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Arcturus Therapeutics Holdings's EBIT history and peer comparisons.

Arcturus Therapeutics Holdings's EBIT decreased from $-58M to $-99M — a 71.1% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Arcturus Therapeutics Holdings's EBIT of $-99M is lower than the Healthcare sector average of $22B. That is roughly 100.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Arcturus Therapeutics Holdings reported $-99M in EBIT as of June 2026. That compares with $-58M in the prior-year period — down 71.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-99M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Arcturus Therapeutics Holdings, and consider following ARCT for alerts when major investors trade the stock.